314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
The Readout Loud
00:00
Challenges and Changes at Gilead Sciences
This chapter delves into the departure of Gilead's R&D chief and chief medical officer, shedding light on the innovation struggles faced by big biotech companies like Pfizer. It explores Gilead's successes in HIV drug treatments but also their challenges in diversifying into cancer treatments, prompting the need for a new direction in research and development.
Transcript
Play full episode
